Sanofi has added another dimension to the use of artificial intelligence (AI) to seek out new drugs, partnering with BioMap on a project to find biologic therapies in a de
Shares in EuroAPI, the active pharmaceutical ingredients (API) business spun out of Sanofi last year, have fallen sharply on the back of a sharp slowdown in sales.
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva
Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major caus
The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect newborns and infants from the virus after an advisor
Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea